A novel long-acting C5a-blocking cyclic peptide prevents sepsis-induced organ dysfunction via effective blockade of the inflammatory cascade
8.5
来源：
Nature
关键字：
mRNA
发布时间：
2025-11-05 11:32
摘要：
Cp1 is a novel long-acting cyclic peptide designed to block C5a, a key mediator in sepsis-induced inflammation. In preclinical studies, it demonstrated significant efficacy in reducing inflammatory responses, improving organ function, and prolonging survival in septic mice. The peptide showed excellent plasma stability and a unique mechanism of action, making it a promising candidate for sepsis therapy.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
1.0分+1.0分
scientific_rigor
1.5分+1.5分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
1.0分+1.0分
关键证据
Cp1 significantly suppressed inflammatory factors and improved survival in septic mice.
The cyclic peptide showed enhanced plasma stability and binding affinity.
Cp1 effectively mitigated organ dysfunction and bacterial burden in sepsis models.
真实性检查
否
AI评分总结
Cp1 is a novel long-acting cyclic peptide designed to block C5a, a key mediator in sepsis-induced inflammation. In preclinical studies, it demonstrated significant efficacy in reducing inflammatory responses, improving organ function, and prolonging survival in septic mice. The peptide showed excellent plasma stability and a unique mechanism of action, making it a promising candidate for sepsis therapy.